Emerging Asthma Agents That Offer the Convenience of Once-Daily Dosing Will Generate More Than $2 Billion in Sales in 2019

GlaxoSmithKline/Theravance’s Relovair Will Emerge as the Market Leader Among Once-Daily LABA/ICS Combinations, According to Findings from Decision Resources

BURLINGTON, Mass.--(BUSINESS WIRE)-- Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that—at the expense of market-leading drugs that are dosed twice daily—emerging agents that offer the convenience of once-daily dosing will generate more than $2 billion in sales in 2019 in the asthma drug market. Driving these sales will be the uptake of emerging once-daily long-acting beta2 agonist (LABA)/inhaled corticosteroid (ICS) combinations such as GlaxoSmithKline/Theravance’s Relovair, Novartis’s indacaterol/mometasone and Chiesi’s carmoterol/budesonide.

The findings from the Pharmacor topic entitled Asthma reveal that Relovair will emerge as the market leader among once-daily LABA/ICS combinations as GlaxoSmithKline wages an aggressive campaign to switch patients off of Advair/Seretide/Adoair prior to branded-generic entry in the United States and generic and branded-generic entry in Europe. As the only once-daily LABA/ICS combination expected to launch in the United States and as a result of its high price, Relovair will garner nearly one-third of sales within the LABA/ICS drug class by 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.

“Although emerging therapies with novel mechanisms of action aim to offer new treatment options for patients with severe corticosteroid-refractory asthma, we expect only interleukin inhibitors to launch and provide a treatment option for this subgroup of patients before 2019,” said Decision Resources Analyst Amanda Puffer.

The findings also reveal that although Genentech/Novartis’s Xolair will be joined by the launch of emerging interleukin inhibitors as treatment options for severe asthma patients before 2019, the use of novel interleukin inhibitors is expected to be restricted to patients with high eosinophils. Use of emerging therapies with novel mechanisms of action, such as chemokine receptor antagonists, are also likely to be restricted to a distinct subgroup of asthma patients.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.



CONTACT:

Decision Resources, Inc.
Christopher Comfort, 781-993-2597
[email protected]

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical  Other Health  General Health

MEDIA:

Logo
 Logo

Suggested Articles

German viral vector CDMO Vibalogics has hired Lonza veteran Tom Hochuli as global CEO to help lead its U.S. expansion efforts.

Merck’s Keytruda already boasts an OK in some esophageal cancer patients, but it’s looking to widen its reach in the tough-to-treat disease.

GI cancers are stubborn, as plenty of oncology drugmakers know. But BMS' Opdivo has broken through with two potentially practice-changing trials.